Back to search results
NCT06608511

Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

Active, Not Recruiting
Not specifiedAges 18+Observational
University of Wisconsin, Madison
~20 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:Blood draw for the laboratory assessment

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in tumor-derived exosomes and progression free survival
Measured over Baseline to progression, up to 3 years
+8 more outcomes measured

Conditions

Skin Cancer
Melanoma (Skin Cancer)
Basal Cell Carcinoma of Skin
Basal Cell Carcinoma of Skin, Site Unspecified
Cutaneous Squamous Cell Carcinoma (CSCC)
Merkel Cell Carcinoma of Skin

Explore related trials

Basal Cell CarcinomaMelanomaMerkel Cell CarcinomaSkin Squamous Cell Carcinoma

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Vincent Ma, MD · PRINCIPAL_INVESTIGATOR · University of Wisconsin, Madison

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years.
Participants must meet at least one of the following criteria:
Finding suspicious of melanoma or non-melanoma skin cancer based on clinical, radiographic, or laboratory findings. Non-melanoma skin cancers include: basal cell carcinoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma.
A confirmed diagnosis of melanoma or non-melanoma skin cancer.

Exclusion

Vulnerable populations, including pregnant women, those who lack consent capacity, the mentally ill, prisoners, cognitively impaired persons, children (age \<18), and UW employees that report to the investigator(s) or to study team members.
Not suitable for study participation due to other reasons at the discretion of the investigators.

What this trial measures

  • Change in tumor-derived exosomes and progression free survivalBaseline to progression, up to 3 years

    To investigate whether changes in tumor-derived exomes measured in serum could represent a potential prognostic biomarker, measured as progression free survival (the duration of time from Day 1 of treatment to time of progression based on clinical or radiographic grounds) or death as a results of any cause, whichever occurs first.

  • Change in circulating tumor cells and progression free survivalBaseline to progression, up to 3 years

    To investigate whether changes in circulating tumor cells measured in serum could represent a potential prognostic biomarker, measured as progression free survival (PFS). PFS is the duration of time from Day 1 of treatment to time of progression (based on clinical or radiographic grounds) or death as a result of any cause, whichever occurs first.

  • Change in circulating tumor DNA and progression free survivalBaseline to progression, up to 3 years

    To investigate whether changes in circulating tumor DNA measured in serum could represent a potential prognostic biomarker, measured as progression free survival. PFS is the duration of time from Day 1 of treatment to time of progression (based on clinical or radiographic grounds) or death as a result of any cause, whichever occurs first

  • Change in tumor-derived exosomes and overall survivalBaseline to progression, up to 3 years

    To investigate whether changes in tumor-derived exomes measured in serum could represent a potential prognostic biomarker measured as overall survival (OS). OS - the duration of time from Day 1 of treatment to time of death as a result of any cause.

  • Change in circulating tumor cells and overall survivalBaseline to progression, up to 3 years

    To investigate whether changes in circulating tumor cells measured in serum could represent a potential prognostic biomarker measured as overall survival. OS - the duration of time from Day 1 of treatment to time of death as a result of any cause.

  • Change in circulating tumor DNA and overall survivalBaseline to progression, up to 3 years

    To investigate whether changes in circulating tumor DNA measured in serum could represent a potential prognostic biomarker measured as overall survival. OS - the duration of time from Day 1 of treatment to time of death as a result of any cause

  • Change in tumor-derived exosomes and treatment responseBaseline to progression, up to 3 years

    To investigate whether changes in tumor-derived exomes measured in serum could represent a potential prognostic biomarker measured as treatment response. Treatment response - rate of objective response (partial response + complete response) and disease control rate (stable disease + partial response + complete response) per RECIST v1.1

  • Change in circulating tumor cells and treatment responseBaseline to progression, up to 3 years

    To investigate whether changes in circulating tumor cells measured in serum could represent a potential prognostic biomarker measured as response to treatment. Treatment response - rate of objective response (partial response + complete response) and disease control rate (stable disease + partial response + complete response) per RECIST v1.1

  • Change in circulating tumor DNA and treatment responseBaseline to progression, up to 3 years

    To investigate whether changes in circulating tumor DNA measured in serum could represent a potential prognostic biomarker measured as response to treatment. Treatment response - rate of objective response (partial response + complete response) and disease control rate (stable disease + partial response + complete response) per RECIST v1.1